MoonLake Immunotherapeutics
MLTX
We are a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. We are currently a single asset company focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from MHKDG and that has the potential, based on response levels seen in clinical trials, to…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$273M
▼ -91.1% YoY
Op. Margin
–
ROIC
-50.03%
▼ -22.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$244M
▼ -67.4% YoY
Op. Cash Flow (TTM)
-$244M
▼ -68.1% YoY
Net Debt
-$397M
Net Cash Position
Cash & Equiv.
$498M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with MLTX
Held by ETFs
MLTX is in 14 US ETFs. The largest of them, with MLTX's weight in each:
Vanguard Health Care ETFVHT0.01%of the fund
Fidelity Nasdaq Composite Index ETFONEQ0.00%of the fund
T. Rowe Price Capital Appreciation Equity ETFTCAF0.04%of the fund
Fidelity MSCI Health Care Index ETFFHLC0.01%of the fund
iShares ESG Aware MSCI USA Small-Cap ETFESML0.04%of the fund
Nuveen ESG Small-Cap ETFNUSC0.05%of the fund
MoonLake Immunotherapeutics (MLTX) in two numbers
Questions about MoonLake Immunotherapeutics
Does MoonLake Immunotherapeutics (MLTX) pay a dividend?
No. MoonLake Immunotherapeutics (MLTX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 1 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in MLTX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MLTX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.